In 2010, the results of the Trastuzumab for Gastric cancer (ToGA) trial displayed how a combination of trastuzumab and chemotherapy was able to prolong the overall survival compared to chemotherapy alone in gastric cancer patients with HER2 overexpression. Here, ERBB2 is linked to gastric cancer.